{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:56:59Z","timestamp":1773295019902,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.04.025","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T05:54:24Z","timestamp":1649742864000},"page":"3027-3037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021"],"prefix":"10.1016","volume":"40","author":[{"given":"Toon","family":"Braeye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Catteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Brondeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris A.F.","family":"van Loenhout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiaan","family":"Proesmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Van Oyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Stouten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Hubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Billuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achille","family":"Djiena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Mahieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naima","family":"Hammami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Van Cauteren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Wyndham-Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2022.04.025_b0005","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S1473-3099(21)00472-2","article-title":"Prevention of host-to-host transmission by SARS-CoV-2 vaccines","volume":"22","author":"Mostaghimi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.025_b0010","first-page":"2100640","article-title":"Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021","volume":"26","author":"de Gier","year":"2021","journal-title":"Eurosurveillance"},{"issue":"39","key":"10.1016\/j.vaccine.2022.04.025_b0015","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1016\/j.vaccine.2021.08.060","article-title":"Vaccine effectiveness against infection and onwards transmission of COVID-19: analysis of Belgian contact tracing data, January\u2013June 2021","volume":"39","author":"Braeye","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.025_b0020","first-page":"null","article-title":"Phase 3 trial of mRNA-1273 during the delta-variant surge","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"10309","key":"10.1016\/j.vaccine.2022.04.025_b0025","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2022.04.025_b0030","doi-asserted-by":"crossref","unstructured":"Israel A, Merzon E, Sch\u00e4ffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ 2021; 375: e067873.","DOI":"10.1136\/bmj-2021-067873"},{"key":"10.1016\/j.vaccine.2022.04.025_b0035","unstructured":"Sciensano. COVID-19 procedures. <https:\/\/covid-19.sciensano.be\/sites\/default\/files\/Covid19\/COVID-19_FAQ_ENG_final.pdf> [accessed July 13, 2021]."},{"key":"10.1016\/j.vaccine.2022.04.025_b0040","unstructured":"Sciensano. COVID-19 FAQ. <https:\/\/covid-19.sciensano.be\/sites\/default\/files\/Covid19\/COVID-19_FAQ_ENG_final.pdf> [accessed July 13, 2021]."},{"key":"10.1016\/j.vaccine.2022.04.025_b0045","unstructured":"Glanville D. COVID-1vaccines: key facts. Eur Med Agency. published online Sept 14; 2020. <https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/vaccines-covid-19\/covid-19-vaccines-key-facts> [accessed Dec 7, 2021]."},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.025_b0050","doi-asserted-by":"crossref","first-page":"e2132540","DOI":"10.1001\/jamanetworkopen.2021.32540","article-title":"Analysis of the effectiveness of the Ad26.COV2.S adenoviral vector vaccine for preventing COVID-19","volume":"4","author":"Corchado-Garcia","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2022.04.025_b0055","unstructured":"Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science 0: eabm0620."},{"key":"10.1016\/j.vaccine.2022.04.025_b0060","unstructured":"Reynolds CJ, Gibbons JM, Pade C, et al. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science 0: eabm0811."},{"issue":"32","key":"10.1016\/j.vaccine.2022.04.025_b0065","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.15585\/mmwr.mm7032e1","article-title":"Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination \u2014 Kentucky, May\u2013June 2021","volume":"70","author":"Cavanaugh","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10318","key":"10.1016\/j.vaccine.2022.04.025_b0070","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.vaccine.2022.04.025_b0075","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.025_b0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1473-3099(21)00676-9","article-title":"Protective immunity after recovery from SARS-CoV-2 infection","volume":"22","author":"Kojima","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.025_b0085","doi-asserted-by":"crossref","first-page":"eabh1766","DOI":"10.1126\/science.abh1766","article-title":"Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants","volume":"373","author":"Wang","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.04.025_b0090","doi-asserted-by":"crossref","unstructured":"Laurie MT, Liu J, Sunshine S, et al. SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron. medRxiv; 2021. 2021.09.08.21263095.","DOI":"10.1101\/2021.09.08.21263095"},{"issue":"10328","key":"10.1016\/j.vaccine.2022.04.025_b0095","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.04.025_b0100","doi-asserted-by":"crossref","unstructured":"Hall VJ, Foulkes S, Insalata F, et al. Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection; findings from the UK SIREN prospective cohort study of healthcare workers March 20 to September 2021; 2021.","DOI":"10.1101\/2021.11.29.21267006"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.025_b0105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"10327","key":"10.1016\/j.vaccine.2022.04.025_b0110","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0140-6736(22)00089-7","article-title":"Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden","volume":"399","author":"Nordstr\u00f6m","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.04.025_b0115","doi-asserted-by":"crossref","unstructured":"Salvagno GL, Brandon M. Henry, Pighi L, De Nitto S, Lippi G. Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers. Rochester, NY: Social Science Research Network; 2021. doi:10.2139\/ssrn.3915349.","DOI":"10.2139\/ssrn.3915349"},{"issue":"24","key":"10.1016\/j.vaccine.2022.04.025_b0120","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.04.025_b0125","doi-asserted-by":"crossref","unstructured":"Meyer M, Constancias F, Worth C, et al. Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds; 2021.","DOI":"10.1101\/2021.11.19.21266252"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.025_b0130","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc2103825","article-title":"SARS-CoV-2 antibody response in persons with past natural infection","volume":"385","author":"Anichini","year":"2021","journal-title":"N Engl J Med"},{"issue":"6585","key":"10.1016\/j.vaccine.2022.04.025_b0135","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.abl4292","article-title":"Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel","volume":"375","author":"Prunas","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.04.025_b0140","doi-asserted-by":"crossref","unstructured":"Clifford S, Waight P, Hackman J, et al. Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission \u2013 a prospective cohort study in England; 2021.","DOI":"10.1101\/2021.11.24.21266401"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.025_b0145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1056\/NEJMc2107717","article-title":"Effect of vaccination on household transmission of SARS-CoV-2 in England","volume":"385","author":"Harris","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.vaccine.2022.04.025_b0150","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMc2106757","article-title":"Effect of vaccination on transmission of SARS-CoV-2","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.04.025_b0155","first-page":"100299","article-title":"Impact of delta variant and vaccination on SARS-CoV-2 secondary attack rate among household close contacts","volume":"17","author":"Ng","year":"2021","journal-title":"Lancet Reg Health \u2013 West Pac"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.025_b0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","article-title":"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study","volume":"22","author":"Singanayagam","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.025_b0165","doi-asserted-by":"crossref","unstructured":"Gier B de, Andeweg S, Backer JA, et al. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021. Eurosurveillance 2021; 26: 2100977.","DOI":"10.2807\/1560-7917.ES.2021.26.44.2100977"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.025_b0170","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMoa2116597","article-title":"Effect of Covid-19 vaccination on transmission of alpha and delta variants","volume":"386","author":"Eyre","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.04.025_b0175","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m P, Ballin M, Nordstr\u00f6m A. Effectiveness of Covid-19 vaccination against risk of symptomatic infection, hospitalization, and death up to 9 months: a Swedish total-population cohort study. Rochester, NY: Social Science Research Network; 2021. doi:10.2139\/ssrn.3949410.","DOI":"10.2139\/ssrn.3949410"},{"key":"10.1016\/j.vaccine.2022.04.025_b0180","doi-asserted-by":"crossref","unstructured":"Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK; 2021.","DOI":"10.1101\/2021.09.15.21263583"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.025_b0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26672-3","article-title":"Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine","volume":"12","author":"Mizrahi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2022.04.025_b0190","first-page":"100252","article-title":"Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study","volume":"12","author":"Allen","year":"2022","journal-title":"Lancet Reg Health"},{"key":"10.1016\/j.vaccine.2022.04.025_b0195","doi-asserted-by":"crossref","unstructured":"Franco N, Coletti P, Willem L, et al. Inferring age-specific differences in susceptibility to and infectiousness upon SARS-CoV-2 infection based on Belgian social contact data; 2021. ArXiv211004207 Q-Bio Stat; published online Oct 8. <http:\/\/arxiv.org\/abs\/2110.04207> [accessed Oct 26, 2021].","DOI":"10.1101\/2021.10.10.21264753"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.025_b0200","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27202-x","article-title":"Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load","volume":"12","author":"Lyngse","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.025_b0205","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2022.04.025_b0210","unstructured":"Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 0, eab3435."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T07:37:32Z","timestamp":1718437052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22004418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":42,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22004418"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}